Dare Bioscience, Inc. (DARE) Reports Q4 Loss, Misses Revenue Estimates

Company Performance - Dare Bioscience reported a quarterly loss of $0.64 per share, slightly better than the Zacks Consensus Estimate of a loss of $0.66, and an improvement from a loss of $0.72 per share a year ago, indicating an earnings surprise of 3.03% [1] - The company posted revenues of -$0.06 million for the quarter ended December 2024, missing the Zacks Consensus Estimate by 101.60%, compared to revenues of $1.81 million in the same quarter last year [2] - Over the last four quarters, Dare Bioscience has surpassed consensus EPS estimates three times but has not been able to beat consensus revenue estimates [2] Stock Outlook - Dare Bioscience shares have declined approximately 7.7% since the beginning of the year, while the S&P 500 has decreased by 5.1% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.65 on revenues of $0.6 million, and for the current fiscal year, it is -$1.90 on revenues of $9.81 million [7] Industry Context - The Medical - Biomedical and Genetics industry, to which Dare Bioscience belongs, is currently ranked in the top 27% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]